It’s also not clear that HHS has the regulatory authority to enforce its threat without going through a formal rulemaking process, lawyers and dietitians say.

Botulinum toxin may slightly reduce monthly migraine days but has higher discontinuation rates due to adverse events.

Glucagon-like peptide-1 (GLP-1) receptor agonists may be a potential novel treatment for alcohol use disorder, according to a ...

This marks a shift from years of aggressive regulation against flavored vapes after the FDA rejected marketing approvals for more than 1 million flavored products.

Bladder-intact disease-free survival was 60% 2 years posttreatment with pembrolizumab combined with gemcitabine-based chemoradiation.

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.

The pause issued by Alito will last until at least May 11, according to The Times, when the full court will then determine how to move forward. HealthDay News — US Supreme Court Justice Samuel Alito ...

Real-time continuous glucose monitoring (CGM) improves blood glucose management in adults with type 2 diabetes managed with basal insulin, according to a study ...

A larger percentage of patients in PFA group had treatment success at 12 months compared with those receiving antiarrhythmic-drug therapy.

Researchers found that both products alone and in combination were safe, with no related serious adverse events in mothers or infants. HealthDay News — Maternal respiratory syncytial virus (RSV) ...